Dados do Trabalho

Título

Biophotonic serum platform for sustainable hepatitis D screening based in a large patient cohort from the Brazilian Amazon

Introdução

Hepatitis delta virus (HDV) is a small spherical virus, a member of the family Kolmioviridae. A distinctive feature of HDV is its dependence on the hepatitis B virus to complete its multiplication cycle. Hepatitis delta virus (HDV) infection carries the worst prognosis among viral hepatitis, thus chronic patients infected with both HBV and HDV face a high risk of developing liver cirrhosis, hepatocellular carcinoma, and liver-related mortality. Estimates of global HDV prevalence range widely, from 12 million to 72 million, with a significant proportion of cases remaining undiagnosed. 

Objetivo (s)

This study aimed to develop an HDV screening strategy 

Material e Métodos

A reagent-free ATR-FTIR platform was used based on 359 blood serum samples collected from patients in the Amazon region of Brazil: 87 anti-HBs negative controls; 94 anti-HBs positive controls; 93 patients with hepatitis B; and 85 patients with hepatitis D (anti-HDV+). Ethical approval was obtained (CAAE: #44208621.2.0000.5152).

Resultados e Conclusão

As a result, using the support vector machine (SVM) algorithms, the study achieved an accuracy of 80%, 82%, and 74% in discriminating hepatitis D (anti-HDV+) patients from anti-HBs negative controls, anti-HBs positive controls, and hepatitis B patients, respectively. In subset with 50 active infection samples based on positive HDV RNA, the accuracy to detect hepatitis D was 88%, 87%, and 88% comparing with anti-HBs negative controls, anti-HBs positive controls, and hepatitis B patients, respectively. These clinical findings underscore the potential of a combined high-throughput, portable, and sustainable ATR-FTIR platform supported by machine learning algorithms as a screening tool for hepatitis D detection.

Palavras Chave

HDV; ATR-FTIR; screening; sustainability; biophotonic